INTRAHEPATIC CHOLESTASIS OF PREGNANCY
ACUTE FATTY LIVER OF PREGNANCY
NONALCOHOLIC FATTY LIVER DISEASE
ACUTE ACETAMINOPHEN OVERDOSE
Disorders of the liver, gallbladder, and pancreas together comprise a formidable list of complications that may arise in pregnancy from preexisting conditions or from some that are unique to pregnancy. The relationships of several of these with pregnancy can be fascinating, intriguing, and challenging.
It is customary to divide liver diseases complicating pregnancy into three general categories. The first includes those specifically related to pregnancy that resolve either spontaneously or following delivery. Examples are hepatic dysfunction from hyperemesis gravidarum, intrahepatic cholestasis, acute fatty liver, and hepatocellular damage with preeclampsia—the HELLP syndrome—hemolysis, elevated serum liver aminotransferase levels, and low platelet counts (Mufti, 2012; Reau, 2014). The second category includes acute hepatic disorders that are coincidental to pregnancy, such as acute viral hepatitis. The third category includes chronic liver diseases that predate pregnancy, such as chronic hepatitis, cirrhosis, or esophageal varices.
There are several pregnancy-induced physiological changes that induce appreciable liver-related clinical and laboratory manifestations (Chap. 4, p. 67, and Appendix, p. 1289). Findings such as elevated serum alkaline phosphatase levels, palmar erythema, and spider angiomas, which might suggest liver disease, are commonly found during normal pregnancy. Metabolism is also affected, due to altered expression of the cytochrome P450 system that is mediated by higher levels of estrogen, progesterone, and other hormones. For example, in pregnancy, hepatic CYP1A2 expression is decreased, whereas that of CYP2D6 and CYP3A4 is increased. Importantly, cytochrome enzymes are expressed in many organs besides the liver, most notably the placenta. The net effect is complex and likely influenced by gestational age and organ of expression (Isoherranen, 2013). Despite all of these functional changes, no major hepatic histological changes are induced by normal pregnancy.
Pernicious nausea and vomiting of pregnancy may involve the liver. There may be mild hyperbilirubinemia with serum aminotransferase levels elevated in up to half of women hospitalized. However, these levels seldom exceed 200 U/L (Table 55-1). Liver biopsy may show minimal fatty changes. Hyperemesis gravidarum is discussed in detail in Chapter 54 (p. 1070).
TABLE 55-1. Clinical and Laboratory Findings with Acute Liver Diseases in Pregnancy
Intrahepatic Cholestasis of Pregnancy
This disorder also has been referred to as recurrent jaundice of pregnancy, cholestatic hepatosis, and icterus gravidarum. It is characterized clinically by pruritus, icterus, or both. It may be more common in multifetal pregnancy, and there is a significant genetic influence (Lausman, 2008; Webb, 2014). Because of this, the incidence of the disorder varies by population. For example, cholestasis is uncommon in North America, with an overall incidence of approximately 1 in 500 to 1000 pregnancies, but is as high as 5.6 percent among Latina women in Los Angeles (Lee, 2006). In Israel, the incidence reported by Sheiner and associates (2006) is approximately 1 in 400. In Sweden, it is 1.5 percent, and in Chile, it is 4 percent (Glantz, 2004; Lee, 2006; Reyes, 1997).
The cause of obstetrical cholestasis is unknown. Both increases and decreases in sex steroid levels have been implicated, but current research centers on the numerous mutations that have been identified in the many genes that control hepatocellular transport systems. One example involves mutations of the ABCB4 gene, which encodes multidrug resistance protein 3 (MDR3) associated with progressive familial intrahepatic cholestasis, as well as a bile salt export pump encoded by ABCB11 (Anzivino, 2013; Davit-Spraul, 2010, 2012; Dixon, 2014). Other potential gene products of interest include the Farnesoid X receptor and transporting ATPase encoded by ATP8B1 (Davit-Spraul, 2012; Müllenbach, 2005). Some drugs that similarly decrease canalicular transport of bile acids aggravate the disorder. For example, we have encountered impressive cholestatic jaundice in pregnant women taking azathioprine following renal transplantation.
Whatever the inciting cause(s), bile acids are cleared incompletely and accumulate in plasma. Hyperbilirubinemia results from retention of conjugated pigment, but total plasma concentrations rarely exceed 4 to 5 mg/dL. Alkaline phosphatase is usually elevated even more so than in normal pregnancy. Serum aminotransferase levels are normal to moderately elevated but seldom exceed 250 U/L (see Table 55-1). Liver biopsy shows mild cholestasis with bile plugs in the hepatocytes and canaliculi of the centrilobular regions, but without inflammation or necrosis. These changes disappear after delivery but often recur in subsequent pregnancies or with estrogen-containing contraceptives.
Pruritus develops in late pregnancy, although it occasionally manifests earlier. There are no constitutional symptoms, and generalized pruritus shows predilection for the soles. Skin changes are limited to excoriations from scratching. Biochemical tests may be abnormal at presentation, but pruritus may precede laboratory findings by several weeks. Approximately 10 percent of women have jaundice.
With normal liver enzymes, the differential diagnosis of pruritus includes other skin disorders (Chap. 62, p. 1214). Findings are unlikely to be due to preeclamptic liver disease if there are no blood pressure changes or proteinuria. Sonography may be warranted to exclude cholelithiasis and biliary obstruction. Acute viral hepatitis is an unlikely diagnosis because of the usually low serum aminotransferase levels seen with cholestasis. Conversely, chronic hepatitis C is associated with a significantly increased risk of cholestasis, which may be as high as 20-fold among women who are hepatitis C RNA positive (Marschall, 2013; Paternoster, 2002).
Pruritus may be troublesome and is thought to result from elevated serum bile salt concentrations. Antihistamines and topical emollients may provide some relief. Although cholestyramine has been reported to be effective, this compound also causes further decreased absorption of fat-soluble vitamins, which may lead to vitamin K deficiency. Fetal coagulopathy may develop, and there are reports of intracranial hemorrhage and stillbirth (Matos, 1997; Sadler, 1995).
A recent metaanalysis suggests that ursodeoxycholic acid relieves pruritus, lowers bile acid and serum enzyme levels, and may reduce certain neonatal complications such as preterm birth, fetal distress, respiratory distress syndrome, and neonatal intensive care unit (NICU) admission (Bacq, 2012). Lucangioli and colleagues (2009) documented an especially profound decrease in serum lithocholic acid levels. Kondrackiene and associates (2005) randomly assigned 84 symptomatic women to receive either ursodeoxycholic acid (8 to 10 mg/kg/d) or cholestyramine (8 g/d). They reported superior relief with ursodeoxycholic acid—67 versus 19 percent, respectively. Similarly, Glantz and coworkers (2005) found superior benefits to women randomly assigned to ursodeoxycholic acid versus dexamethasone. The American College of Obstetricians and Gynecologists (2012a) has concluded that ursodeoxycholic acid both relieves pruritus and improves fetal outcomes, although evidence for the latter is not compelling.
Cholestasis and Pregnancy Outcomes
Earlier reports described excessive adverse pregnancy outcomes in women with cholestatic jaundice. Data accrued during the past two decades are ambiguous concerning increased perinatal mortality rates and whether close fetal surveillance is preventative. A review of a few studies illustrates this. Glantz and colleagues (2004) described outcomes in 693 Swedish women. Perinatal mortality rates were slightly increased, but death was limited to infants of mothers with severe disease characterized by total bile acid levels ≥ 40 μmol/L. Sheiner and coworkers (2006) described no differences in perinatal outcomes in 376 affected pregnancies compared with their overall obstetrical population. There was, however, a significant increase in labor inductions and cesarean deliveries in affected women. Lee and associates (2009) described two cases of sudden fetal death not predicted by nonstress testing. Rook and colleagues (2012) reported outcomes of 101 affected women in Northern California. Although there were no term fetal demises, 87 percent of women underwent labor induction, ostensibly to avoid adverse outcomes. Nonetheless, neonatal complications occurred in a third of the pregnancies, particularly respiratory distress, fetal distress, and meconium-stained amnionic fluid, all of which were reported more frequently with higher total bile acid levels. Finally, Wikström Shemer and coworkers (2013) reported outcomes for a population-based Swedish study of 5477 pregnancies complicated by intrahepatic cholestasis of pregnancy among 1,213,668 singleton deliveries. The authors reported novel associations of cholestasis with preeclampsia and gestational diabetes. Although neonates were more likely to have a low 5-minute Apgar score and to be large for gestational age, there was no increased risk of stillbirth. Importantly, the pregnancies were actively managed to avoid stillbirths, and this was reflected in the higher induction and preterm birth rates. Many recommend early delivery by labor induction to avoid stillbirth.
An intriguing finding indicates that bile acids may cause fetal death. Strehlow and associates (2010) reported that the PR interval on fetal echocardiography was significantly prolonged in women with intrahepatic cholestasis. Gorelik and colleagues (2006) suggest that bile acids may cause fetal cardiac arrest after entering cardiomyocytes in abnormal amounts. Using fetal myocyte cultures, they showed expression of several genes that may play a role in bile transport.
Acute Fatty Liver of Pregnancy
The most common cause of acute liver failure during pregnancy is acute fatty liver—also called acute fatty metamorphosis or acute yellow atrophy. In its worst form, the incidence probably approximates 1 in 10,000 pregnancies (Nelson, 2013). Fatty liver recurring in subsequent pregnancy is uncommon, but a few cases have been described (Usta, 1994).
Fatty liver is characterized by accumulation of microvesicular fat that literally “crowds out” normal hepatocytic function (Fig. 55-1). Grossly, the liver is small, soft, yellow, and greasy.
FIGURE 55-1 Acute fatty liver of pregnancy. Cross section of the liver from a woman who died as the result of pulmonary aspiration and respiratory failure. The liver has a greasy yellow appearance, which was present throughout the entire specimen. Inset: Electron photomicrograph of two swollen hepatocytes containing numerous microvesicular fat droplets (*). The nuclei (N) remain centered within the cells, in contrast to the case with macrovesicular fat deposition. (Photograph contributed by Dr. Don Wheeler.)
Although much has been learned about this disorder, interpretation of conflicting data has led to incomplete but intriguing observations. For example, some if not most cases of maternal fatty liver are associated with recessively inherited mitochondrial abnormalities of fatty acid oxidation. These are similar to those in children with Reye-like syndromes. Several mutations have been described for the mitochondrial trifunctional protein enzyme complex that catalyzes the last oxidative steps in the pathway. The most common are the G1528C and E474Q mutations of the gene on chromosome 2 that code for long-chain-3-hydroxyacyl-CoA-dehydrogenase—known as LCHAD. There are other mutations for medium-dehydrogenase—MCHAD, as well as carnitine palmitoyltransferase 1 (CPT1) deficiency (Santos, 2007; Ylitalo, 2005).
Sims and coworkers (1995) observed that some homozygous LCHAD-deficient children with Reye-like syndromes had heterozygous mothers with fatty liver. This was also seen in women with a compound heterozygous fetus. Although some conclude that only heterozygous LCHAD-deficient mothers are at risk when their fetus is homozygous, this is not always true (Baskin, 2010).
There is a controversial association between fatty acid β-oxidation enzyme defects and severe preeclampsia—especially in women with HELLP syndrome (Chap. 40, p. 742). Most of these observations have been arrived at by retrospectively studying mothers delivered of a child who later developed Reye-like syndrome. For example, Browning and coworkers (2006) performed a case-control study of 50 mothers of children with a fatty-acid oxidation defect and 1250 mothers of matched control infants. During their pregnancy, 16 percent of mothers with an affected child developed liver problems compared with only 0.9 percent of control women. Problems included HELLP syndrome in 12 percent and fatty liver in 4 percent. Despite these findings, the clinical, biochemical, and histopathological findings are sufficiently disparate to suggest that severe preeclampsia, with or without HELLP syndrome, and fatty liver are distinct syndromes (American College of Obstetricians and Gynecologists, 2012a; Sibai, 2007).
Clinical and Laboratory Findings
Acute fatty liver almost always manifests late in pregnancy. Nelson and colleagues (2013) described 51 such women at Parkland Hospital with a mean gestational age of 37 weeks—range 31.7 to 40.9. Almost 20 percent were delivered at 34 weeks’ gestation or earlier. Of these 51 women, 41 percent were nulliparous, and two thirds carried a male fetus. Ten to 20 percent of cases are in women with a multifetal gestation (Fesenmeier, 2005; Vigil-De Gracia, 2011).
Fatty liver has a clinical spectrum of severity. In the worst cases, symptoms usually develop over several days. Persistent nausea and vomiting are major complaints, and there are varying degrees of malaise, anorexia, epigastric pain, and progressive jaundice. Perhaps half of affected women have hypertension, proteinuria, and edema, alone or in combination—signs suggestive of preeclampsia. As shown in Tables55-1 and 55-2, there are variable degrees of moderate to severe liver dysfunction manifest by hypofibrinogenemia, hypoalbuminemia, hypocholesterolemia, and prolonged clotting times. Serum bilirubin levels usually are < 10 mg/dL, and serum aminotransferase levels are modestly elevated and usually < 1000 U/L.
TABLE 55-2. Laboratory Findings in 137 Women with Acute Fatty Liver of Pregnancy
In almost all severe cases, there is profound endothelial cell activation with capillary leakage causing hemoconcentration, acute kidney injury, ascites, and sometimes pulmonary permeability edema (Bernal, 2013). With severe hemoconcentration, uteroplacental perfusion is reduced and this, along with maternal acidosis, can cause fetal death even before presentation for care. Maternal and fetal acidemia is also related to a high incidence of fetal jeopardy with a concordantly high cesarean delivery rate.
Hemolysis can be severe and evidenced by leukocytosis, nucleated red cells, mild to moderate thrombocytopenia, and elevated serum levels of lactic acid dehydrogenase (LDH). Because of hemoconcentration, however, the hematocrit is often within the normal range. The peripheral blood smear demonstrates echinocytosis, and it has been suggested that hemolysis is caused by the effects of hypocholesterolemia on erythrocyte membranes (Cunningham, 1985).
Various liver imaging techniques have been used to confirm the diagnosis, however, none are particularly reliable. Specifically, Castro and associates (1996) reported poor sensitivity for confirmation by sonography—three of 11 patients, computed tomography (CT)—five of 10, and magnetic resonance (MR) imaging—none of five. Similarly, in a prospective evaluation of the Swansea criteria proposed by Ch’ng and coworkers (2002), only a quarter of women had classic sonographic findings such as maternal ascites or an echogenic hepatic appearance (Knight, 2008). Our experiences are similar (Nelson, 2013).
The syndrome typically continues to worsen after diagnosis. Hypoglycemia is common, and obvious hepatic encephalopathy, severe coagulopathy, and some degree of renal failure each develop in approximately half of women. Fortunately, delivery arrests liver function deterioration.
We have encountered several women with a forme fruste of this disorder. Clinical involvement is relatively minor and laboratory aberrations—usually only hemolysis and decreased plasma fibrinogen—herald the syndrome. Thus, the spectrum of liver involvement varies from milder cases that go unnoticed or are attributed to preeclampsia, to overt hepatic failure with encephalopathy.
Coagulopathy. The degree of clotting dysfunction is also variable and can be serious and life threatening, especially if operative delivery is undertaken. Coagulopathy is caused by diminished hepatic procoagulant synthesis, although there is also some evidence for increased consumption with disseminated intravascular coagulation. As shown in Table 55-2, hypofibrinogenemia sometimes is profound. Of 51 women with fatty liver cared for at Parkland Hospital, almost a third had a plasma fibrinogen nadir < 100 mg/dL (Nelson, 2013). Modest elevations of serum d-dimers or fibrin split product levels indicate an element of consumptive coagulopathy. Although usually modest, occasionally there is profound thrombocytopenia (Table 55-2). Among the 51 women from Parkland Hospital, 20 percent had platelet counts < 100,000/μL and 10 percent had platelet counts < 50,000/μL (Nelson, 2013).
Intensive supportive care and good obstetrical management are essential. In some cases, the fetus may be already dead when the diagnosis is made, and the route of delivery is less problematic. Often, viable fetuses tolerate labor poorly. Because significant procrastination in effecting delivery may increase maternal and fetal risks, we prefer a trial of labor induction with close fetal surveillance. Although some recommend cesarean delivery to hasten hepatic healing, this increases maternal risk when there is severe coagulopathy. Nonetheless, cesarean delivery is common, and rates approach 90 percent. Transfusions with whole blood or packed red cells, along with fresh-frozen plasma, cryoprecipitate, and platelets, are usually necessary if surgery is performed or if obstetrical lacerations complicate vaginal delivery (Chap. 41, p. 815).
Hepatic dysfunction resolves postpartum. It usually normalizes within a week, and in the interim, intensive medical support may be required. There are two associated conditions that may develop around this time. Perhaps a fourth of women have evidence for transient diabetes insipidus. This presumably is due to elevated vasopressinase concentrations caused by diminished hepatic production of its inactivating enzyme. Finally, acute pancreatitisdevelops in approximately 20 percent.
With supportive care, recovery usually is complete. Maternal deaths are caused by sepsis, hemorrhage, aspiration, renal failure, pancreatitis, and gastrointestinal bleeding. There were two maternal deaths in the series of 51 women at Parkland Hospital. One was an encephalopathic woman who aspirated before intubation during transfer to Parkland Hospital. The other was in a woman with massive liver failure and nonresponsive hypotension (Nelson, 2013). In some centers, other measures have included plasma exchange and even liver transplantation (Fesenmeier, 2005; Franco, 2000; Martin, 2008).
Maternal and Perinatal Outcomes
Although maternal mortality rates with acute fatty liver of pregnancy have approached 75 percent in the past, the contemporaneous outlook is much better. From his review, Sibai (2007) cites an average mortality rate of 7 percent. He also cited a 70-percent preterm delivery rate and a perinatal mortality rate of approximately 15 percent, which in the past was nearly 90 percent. At Parkland Hospital, the maternal and perinatal mortality rates during the past four decades have been 4 percent and 12 percent, respectively (Nelson, 2013).
Hepatic involvement is relatively common in women with severe preeclampsia and eclampsia (see Table 55-1). These changes are discussed in detail in Chapter 40 (p. 741).
Although most viral hepatitis syndromes are asymptomatic, during the past 25 years, acute symptomatic infections have become even less common in the United States (Centers for Disease Control and Prevention, 2008). There are at least five distinct types of viral hepatitis: A (HAV), B (HBV), D (HDV) caused by the hepatitis B-associated delta agent, C (HCV), and E (HEV). The clinical presentation is similar in all, and although the viruses themselves probably are not hepatotoxic, the immunological response to them causes hepatocellular necrosis (Dienstag, 2012a,b). Asymptomatic chronic viral hepatitis remains the leading cause of liver cancer and the most frequent reason for liver transplantation.
As discussed above, acute infections are most often subclinical and anicteric. When they are clinically apparent, nausea and vomiting, headache, and malaise may precede jaundice by 1 to 2 weeks. Low-grade fever is more common with hepatitis A. By the time jaundice develops, symptoms are usually improving. Serum aminotransferase levels vary, and their peaks do not correspond with disease severity (see Table 55-1). Peak levels that range from 400 to 4000 U/L are usually reached by the time jaundice develops. Serum bilirubin typically continues to rise, despite falling aminotransferase levels, and peaks at 5 to 20 mg/dL.
Any evidence for severe disease should prompt hospitalization. These include incessant nausea and vomiting, prolonged prothrombin time, low serum albumin level, hypoglycemia, high serum bilirubin level, or central nervous system symptoms. In most cases, however, there is complete clinical and biochemical recovery within 1 to 2 months in all cases of hepatitis A, in most cases of hepatitis B, but in only a small proportion of cases of hepatitis C.
When patients are hospitalized, their feces, secretions, bedpans, and other articles in contact with the intestinal tract should be handled with glove-protected hands. Extra precautions, such as double gloving during delivery and surgical procedures, are recommended. Due to significant exposure of health-care personnel to hepatitis B, the Centers for Disease Control and Prevention (CDC) recommend active and passive vaccination. There is no vaccine for hepatitis C, so recommendations are for postexposure serosurveillance only.
Acute hepatitis has a case-fatality rate of 0.1 percent. For patients ill enough to be hospitalized, it is as high as 1 percent. Most fatalities are due to fulminant hepatic necrosis, which in later pregnancy may resemble acute fatty liver. In these cases, hepatic encephalopathy is the usual presentation, and the mortality rate is 80 percent. Approximately half of patients with fulminant disease have hepatitis B infection, and co-infection with the delta agent is common.
The Centers for Disease Control and Prevention (2012) estimates that 4.4 million Americans are living with chronic viral hepatitis. By far, the most frequent complication of hepatitis B and C is subsequent development of chronic hepatitis, which is usually diagnosed serologically (Table 55-3). Chronic infection follows acute hepatitis B in approximately 5 to 10 percent of cases in adults. Most become asymptomatic carriers, but a small percentage have low-grade chronic persistent hepatitis or chronic active hepatitis with or without cirrhosis. With acute hepatitis C, however, chronic hepatitis develops in most patients. With persistently abnormal biochemical tests, liver biopsy usually discloses active inflammation, continuing necrosis, and fibrosis that may lead to cirrhosis. Chronic hepatitis is classified by cause; grade, defined by histological activity; and stage, which is the degree of progression (Dienstag, 2012b). In these cases, there is evidence that a cellular immune reaction is interactive with a genetic predisposition.
TABLE 55-3. Simplified Diagnostic Approach in Patients with Hepatitis
Although most chronically infected persons are asymptomatic, approximately 20 percent develop cirrhosis within 10 to 20 years (Dienstag, 2012b). When present, symptoms are nonspecific and usually include fatigue. Diagnosis can be confirmed by liver biopsy, however, treatment is usually given to patients after serological or virological diagnosis. In some patients, cirrhosis with liver failure or bleeding varices may be the presenting findings. The management of chronic hepatitis B and hepatitis C is discussed in their respective sections.
Chronic Hepatitis and Pregnancy. Most young women with chronic hepatitis either are asymptomatic or have only mild liver disease. For seropositive asymptomatic women, there usually are no problems with pregnancy. With symptomatic chronic active hepatitis, pregnancy outcome depends primarily on disease and fibrosis intensity, and especially on the presence of portal hypertension. The few women whom we have managed have done well, but their long-term prognosis is poor. Accordingly, they should be counseled regarding possible liver transplantation as well as abortion and sterilization options.
Because of vaccination programs, the incidence of hepatitis A has decreased 95 percent since 1995. In 2010, the rate was 0.6 per 100,000 individuals—the lowest rate ever reported in the United States (Centers for Disease Control and Prevention, 2012). This 27-nm RNA picornavirus is transmitted by the fecal–oral route, usually by ingestion of contaminated food or water. The incubation period is approximately 4 weeks. Individuals shed virus in their feces, and during the relatively brief period of viremia, their blood is also infectious. Signs and symptoms are often nonspecific and usually mild, although jaundice develops in most patients. Symptoms usually last less than 2 months, although 10 to 15 percent of patients may remain symptomatic or relapse for up to 6 months (Dienstag, 2012a). Early serological detection is by identification of IgM anti-HAV antibody that may persist for several months. During convalescence, IgG antibody predominates, and it persists and provides subsequent immunity. There is no chronic stage of hepatitis A.
Management of hepatitis A in pregnant women consists of a balanced diet and diminished physical activity. Women with less severe illness may be managed as outpatients. In developed countries, the effects of hepatitis A on pregnancy outcomes are not dramatic (American College of Obstetricians and Gynecologists, 2012a,b). Both perinatal and maternal mortality rates, however, are substantively increased in resource-poor countries. There is no evidence that hepatitis A virus is teratogenic, and transmission to the fetus is negligible. Preterm birth may be increased, and neonatal cholestasis has been reported (Urganci, 2003). Although hepatitis A RNA has been isolated in breast milk, no cases of neonatal hepatitis A have been reported secondary to breast feeding (Daudi, 2012).
Preventatively, vaccination during childhood with formalin-inactivated hepatitis viral vaccine is more than 90-percent effective. HAV vaccination is recommended by the American College of Obstetricians and Gynecologists (2012b) and the Centers for Disease Control and Prevention (2010) for high-risk adults, a category that includes behavioral and occupational populations and travelers to high-risk countries. These countries are listed by the Centers for Disease Control and Prevention in the 2014 CDC Health Information for International Travel “yellow book,” which is available at: http://wwwnc.cdc.gov/travel/yellowbook/2014/table-of-contents.
Passive immunization for the pregnant woman recently exposed by close personal or sexual contact with a person with hepatitis A is provided by a 0.02 mL/kg dose of immune globulin (Centers for Disease Control and Prevention, 2010). Victor and colleagues (2007) reported that a single dose of HAV vaccine given in the usual dosage within 2 weeks of exposure to exposed persons was as effective as immune serum globulin to prevent hepatitis A. In both groups, HAV developed in 3 to 4 percent.
This is a double-stranded DNA virus of the Hepadnaviridae family. It is found worldwide and is endemic in Africa, Central and Southeast Asia, China, Eastern Europe, the Middle East, and certain areas of South America, with prevalence rates as high as 5 to 20 percent. The World Health Organization (2009) estimates that more than two billion people worldwide are infected with HBV, and of these, 370 million have chronic infection. The Centers for Disease Control and Prevention (2012) estimated that there were 43,000 acute hepatitis B cases in the United States in 2010—a decline of more than 80 percent since vaccination was introduced in the 1980s. The World Health Organization considers hepatitis B to be second only to tobacco among human carcinogens.
The hepatitis B virus is transmitted by exposure to blood or body fluids from infected individuals. In endemic countries, vertical transmission, that is, from mother to fetus or newborn, accounts for at least 35 to 50 percent of chronic HBV infections. In low-prevalence countries such as the United States, which has a prevalence < 2 percent, the more frequent mode of HBV transmission is via sexual transmission or sharing of contaminated needles. HBV can be transmitted by any body fluid, but exposure to virus-laden serum is the most efficient.
Acute hepatitis B develops after an incubation period of 30 to 180 days with a mean of 8 to 12 weeks. At least half of acute infections are asymptomatic. If symptoms are present, they are usually mild and include anorexia, nausea, vomiting, fever, abdominal pain, and jaundice. Acute HBV accounts for half of cases of fulminant hepatitis. Complete resolution of symptoms occurs within 3 to 4 months in more than 90 percent of patients. Figure 55-2details the sequence of the various HBV antigens and antibodies in acute infection. The first serological marker to be detected is the hepatitis B surface antigen (HBsAg), often preceding the increase in aminotransferase levels. As HBsAg disappears, antibodies to the surface antigen develop (anti-HBs), marking complete resolution of disease. Hepatitis B core antigen is an intracellular antigen and not detectable in serum. However, anti-HBc is detectable within weeks of HBsAg appearance. The hepatitis Be antigen (HBeAg) is present during times of high viral replication and often correlates with detectable HBV DNA. After acute hepatitis, approximately 90 percent of adult persons recover completely. The 10 percent who remain chronically infected are considered to have chronic hepatitis B.
FIGURE 55-2 Sequence of various antigens and antibodies in acute hepatitis B. ALT = alanine aminotransferase; anti-HBc = antibody to hepatitis B core antigen; anti-HBe = antibody to hepatitis B e antigen; anti-HBs = antibody to hepatitis B surface antigen; HBeAg = hepatitis B e antigen; HBsAg = hepatitis B surface antigen. (Redrawn from Dienstag, 2012a.)
Chronic HBV infection is often asymptomatic but may be clinically suggested by persistent anorexia, weight loss, fatigue, and hepatosplenomegaly. Extrahepatic manifestations may include arthritis, generalized vasculitis, glomerulonephritis, pericarditis, myocarditis, transverse myelitis, and peripheral neuropathy. One risk factor for chronic disease is age at acquisition—more than 90 percent in newborns, 50 percent in young children, and less than 10 percent in immunocompetent adults. Another risk is an immunocompromised state such as those with human immunodeficiency virus (HIV) infection, transplant recipients, or persons receiving chemotherapy. Chronically infected persons may be asymptomatic carriers or have chronic disease with or without cirrhosis. Patients with chronic disease have persistent HBsAg serum positivity. The patients with evidence of high viral replication—HBV DNA with or without HBeAg, have the highest likelihood of developing cirrhosis and hepatocellular carcinoma. HBV DNA has been found to be the best correlate of liver injury and disease progression risk.
Hepatitis B infection is not a cause of excessive maternal morbidity and mortality. It is often asymptomatic and found only on routine prenatal screening (Connell, 2011; Stewart, 2013). A review of the National Inpatient Sample (NIS) Agency for Healthcare Research and Quality reported a modest increase in preterm birth rates in HBV-positive mothers but no effect on fetal-growth restriction or preeclampsia rates (Reddick, 2011). Others have shown similar results (Connell, 2011; Safir, 2010). Transplacental viral infection is uncommon, and Towers and associates (2001) reported that viral DNA is rarely found in amnionic fluid or cord blood. Interestingly, HBV DNA has been found in the ovaries of HBV-positive pregnant women, and the highest levels were found in women who transmitted HBV to their fetuses (Hu, 2012; Lou, 2010; Yu, 2012).
In the absence of HBV immunoprophylaxis, 10 to 20 percent of women positive for HBsAg transmit viral infection to their infant. This rate increases to almost 90 percent if the mother is HBsAg and HBeAg positive. Immunoprophylaxis and hepatitis B vaccine given to infants born to HBV-infected mothers has decreased transmission dramatically and prevented approximately 90 percent of infections (Smith, 2012). But, women with high HBV vital loads—106 to 108 copies/mL, or those who are HBeAg positive, still have a least a 10-percent vertical transmission rate, regardless of immunoprophylaxis.
To decrease vertical transmission in women at highest risk because of high HBV DNA levels, some have recommended antiviral therapy. Lamivudine, a cytidine nucleoside analogue, has been found to significantly decrease the risk of fetal HBV infection in women with high HBV viral loads (Dusheiko, 2012; Giles, 2011; Han, 2011; Shi, 2010; Xu, 2009). Safety data in early pregnancy, although limited, are promising (Yi, 2012; Yu, 2012). Early reports of two other antiviral medications, telbivudine and tenofovir, for use in pregnancy also show promise (Deng, 2012; Han, 2011; Liu, 2013; Pan, 2012a,b). Hepatitis B immunoglobulin (HBIG) given antepartum to women at highest risk of transmission has also been shown to be effective in decreasing transmission rates (Shi, 2010). Antiviral therapy or HBIG has been shown to be cost-effective in recent analyses (Nayeri, 2012).
Infants born to seropositive mothers are given HBIG very soon after birth. This is accompanied by the first of a three-dose hepatitis B recombinant vaccine. Hill and colleagues (2002) applied this strategy in 369 infants and reported that the 2.4-percent transmission rate was not increased with breast feeding if vaccination was completed. Although virus is present in breast milk, the incidence of transmission is not lowered by formula feeding (Shi, 2011). The American Academy of Pediatrics does not consider maternal HBV infection a contraindication to breast feeding.
For high-risk mothers who are seronegative, hepatitis B vaccine can be given during pregnancy. The efficacy has been shown to be similar to that for nonpregnant adults, with overall seroconversion rates approaching 95 percent after three doses (Stewart, 2013). The traditional vaccination schedule of 0, 1, and 6 months may be difficult to complete during a pregnancy, and compliance rates decline after delivery. Sheffield and coworkers (2006) reported that the three-dose regimen given prenatally—initially and at 1 and 4 months—resulted in seroconversion rates of 56, 77, and 90 percent, respectively, This regimen was noted to be easily be completed during routine prenatal care.
Also called delta hepatitis, this is a defective RNA virus that is a hybrid particle with an HBsAg coat and a delta core. The virus must co-infect with hepatitis B either simultaneously or secondarily. It cannot persist in serum longer than hepatitis B virus. Transmission is similar to hepatitis B. Chronic co-infection with B and D hepatitis is more severe and accelerated than with HBV alone, and up to 75 percent of affected patients develop cirrhosis. HDV infection is detected by the presence of anti-HDV and HDV DNA. Neonatal transmission is unusual as neonatal HBV vaccination usually prevents delta hepatitis.
This is a single-stranded RNA virus of the family Flaviviridae. There are at least six major genotypes—type 1 accounts for 70 percent of HCV infections in the United States. Transmission occurs via blood and body fluids, although sexual transmission is inefficient. Up to a third of anti-HCV positive persons have no identifiable risk factors (Dienstag, 2012b). Screening for HCV is recommended for HIV-infected individuals, persons with injection drug use, hemodialysis patients, children born to mothers with HCV, persons exposed to HCV-positive blood or body fluids, persons with unexplained elevations in aminotransferase values, and recipients of blood or transplants before July 1992. Prenatal screening has been recommended in high-risk women, and in the United States, seroprevalence rates as high as 1 to 2.4 percent have been reported (American College of Obstetricians and Gynecologists, 2012b; Arshad, 2011; Connell, 2011). It is higher in women who are HIV positive, and Santiago-Munoz and associates (2005) found that 6.3 percent of HIV-infected pregnant women at Parkland Hospital were co-infected with hepatitis B or C.
Acute HCV infection is usually asymptomatic or with mild symptoms. Only 10 to 15 percent develop jaundice. The incubation period ranges from 15 to 160 days with a mean of 7 weeks. Aminotransferase levels are elevated episodically during the acute infection. Hepatitis C RNA testing is now considered the “gold standard” for the diagnosis of HCV—levels may be detected even before aminotransferase elevations and the development of anti-HCV. Anti-HCV antibody is not detected for an average of 15 weeks and in some cases as long as a year (Dienstag, 2012a).
As many as 80 to 90 percent of patients with acute HCV will be chronically infected. Although most remain asymptomatic, approximately 20 to 30 percent progress to cirrhosis within 20 to 30 years. Aminotransferase values fluctuate, and HCV RNA levels vary over time. Liver biopsy reveals chronic disease and fibrosis in up to 50 percent, however, these findings are often mild. Overall, the long-term prognosis for most patients is excellent.
As expected, most pregnant women diagnosed with HCV have chronic disease. HCV infection was initially thought to have limited pregnancy effects. However, more recent reports have chronicled modestly increased fetal risks for low birthweight, NICU admission, preterm delivery, and mechanical ventilation (Berkley, 2008; Pergam, 2008; Reddick, 2011). In some women, these adverse outcomes may have been influenced by concurrent high-risk behaviors associated with HCV infection.
The primary adverse perinatal outcome is vertical transmission of HCV infection to the fetus-infant. This is higher in mothers with viremia (Indolfi, 2014; Joshi, 2010). From their review, Airoldi and Berghella (2006) cited a rate of 1 to 3 percent in HCV-positive, RNA-negative women compared with 4 to 6 percent in those who were RNA-positive. In a report from Dublin, McMenamin and colleagues (2008) described transmission rates in 545 HCV-positive women. They found a 7.1-percent vertical transmission rate in RNA-positive women compared with none in those who were RNA-negative. Some have found an even greater risk when the mother is co-infected with HIV (Ferrero, 2003). Approximately two thirds of prenatal transmission occurs peripartum. HCV genotype, invasive prenatal procedures, breast feeding, and delivery mode are not associated with mother-to-child transmission (Babik, 2011; Cottrell, 2013; Ghamar Chehreh, 2011; López, 2010). That said, invasive procedures such as internal electronic fetal heart rate monitoring should be avoided. HCV infection is not a contraindication to breast feeding.
There is currently no licensed vaccine for HCV prevention. The chronic HCV infection treatment has traditionally included alpha interferon (standard and pegylated), alone or in combination with ribavirin. This regimen is contraindicated in pregnancy because of the teratogenic potential of ribavirin in animals (Joshi, 2010). The initial 5-year review of the Ribavirin Pregnancy Registry found no evidence for human teratogenicity. However, the registry has enrolled fewer than half of the necessary numbers to allow a conclusive statement to be made (Roberts, 2010). The development and study of direct acting and host-targeted antiviral drugs in the past decade has shown great promise for the management of chronic hepatitis C (Liang, 2013; Lok, 2012; Poordad, 2013). Current interferon-free, ribavirin-free regimens are being evaluated, although no data are available for pregnant women.
This water-borne RNA virus usually is enterically transmitted by contaminated water supplies. Hepatitis E is probably the most common cause of acute hepatitis (Hoofnagle, 2012). It causes epidemic outbreaks in third-world countries with substantial morbidity and mortality rates. Pregnant women have a higher case-fatality rate than nonpregnant individuals. Rein and coworkers (2012) suggested a 20-percent mortality rate using modeling estimates from the developing world. Fulminant hepatitis, although rare overall, is more common in pregnant women and contributes to the increased mortality rates (Labrique, 2012; Mehta, 2012).
Higher hepatitis E viral loads and increased cytokine secretion in pregnant compared with nonpregnant women may be factors in the development of fulminant hepatitis (Borkakoti, 2013; Salam, 2013). Recombinant HEV vaccine efficacy is reported to be > 90 percent, and preliminary data from inadvertently vaccinated pregnant women have shown no adverse maternal or fetal events. Even so, there is no currently available Food and Drug Administration (FDA)-approved vaccine (Labrique, 2012; Wedemeyer, 2012; Wu, 2012).
This blood-borne infection with a flavivirus-like RNA virus does not actually cause hepatitis (Dienstag, 2012a). Its seroprevalence ranges from 0.08 to 5 percent, and there is currently no recommended treatment aside from basic blood and body fluid precautions. Infant transmission has been described (Feucht, 1996; Inaba, 1997).
This is a generally progressive chronic hepatitis that is important to distinguish from chronic viral hepatitis because treatments are markedly different. According to Krawitt (2006), an environmental agent—a virus or drug—triggers events that mediate T cells to destroy liver antigens in genetically susceptible patients. Type 1 hepatitis is more common and is characterized by multiple autoimmune antibodies such as antinuclear antibodies (ANA) as well as certain human leukocyte genes. Treatment employs corticosteroids, alone or combined with azathioprine (Gossard, 2012). In some patients, cirrhosis or hepatocellular carcinoma develops.
As with other autoimmune disorders, chronic autoimmune hepatitis is more common in women and frequently coexists with thyroiditis, ulcerative colitis, type 1 diabetes, and rheumatoid arthritis. Hepatitis is usually subclinical, but exacerbations can cause fatigue and malaise that can be debilitating.
In general, pregnancy outcomes of women with autoimmune hepatitis are poor, but the prognosis is good with well-controlled disease (Uribe, 2006). In one study, Schramm and colleagues (2006) described 42 pregnancies in 22 German women with autoimmune hepatitis. A fifth had a flare antepartum, and half had a flare postpartum. One woman underwent liver transplantation at 18 weeks’ gestation, and another died of sepsis at 19 weeks. In their 38-year review, Candia and associates (2005) found 101 pregnancies in 58 women. They reported that preeclampsia developed in approximately a fourth, and there were two maternal deaths. Westbrook and coworkers (2012) reported the outcomes of 81 pregnancies in 53 women. Flares occurred in a third of the women. There were more common in those not taking medication and those with active disease in the year before conception. Only a minority—20 of 81—were not taking medications. Maternal and fetal complications were higher among women with cirrhosis, particularly with respect to the risks of death or need for liver transplantation during the pregnancy or within 12 months postpartum.
Nonalcoholic Fatty Liver Disease
Steatohepatitis is an increasingly recognized condition that may occasionally progress to hepatic cirrhosis. As a macrovesicular fatty liver condition, it resembles alcohol-induced liver injury but is seen without alcohol abuse. Obesity, type 2 diabetes, and hyperlipidemia—syndrome X—frequently coexist and likely are etiological agents or “triggers” (McCullough, 2006). Nonalcoholic fatty liver disease (NAFLD) is common in obese persons, and as many as 50 percent of the morbidly obese are affected (Chap. 48, p. 963). Moreover, half of persons with type 2 diabetes have NAFLD. Browning and associates (2004) used magnetic resonance spectroscopy to determine the prevalence of NAFLD in Dallas County and found that approximately a third of adults were affected. This varied by ethnicity, with 45 percent of Hispanics, 33 percent of whites, and 24 percent of blacks being affected. Most people—80 percent—found to have steatosis had normal liver enzymes. Welsh and colleagues (2013) showed that nonalcoholic fatty liver disease among adolescents increased from 3.9 to 10.7 percent between 1988 to 1994 and 2007 to 2010. The risk increased with age, body mass index, male gender, and Mexican American race. And half of obese male adolescents are affected.
There is a continuum or spectrum of liver damage in which fatty liver progresses to nonalcoholic steatohepatitis—NASH, and then hepatic fibrosis develops that may progress to cirrhosis (Levene, 2012). Still, in most persons, the disease is usually asymptomatic, and it is a frequent explanation for elevated aminotransferase levels found in blood donors and other routine screening testing. Indeed, it is the cause of elevated asymptomatic aminotransferase levels in up to 90 percent of cases in which other liver disease is excluded. It also is the most common cause of abnormal liver tests among adults in this country. Currently, weight loss along with diabetes and dyslipidemia control is the only recommended treatment.
Fatty liver infiltration is probably much more common than realized in obese and diabetic pregnant women. During the past decade, we encountered an increasing number of pregnant women with these disorders. Once severe liver injury, that is, acute fatty liver of pregnancy, was excluded, gravidas with fatty liver infiltration had no adverse outcomes relative to liver involvement. Page and Girling (2011) reported five women who had mild liver enzyme abnormalities after exclusion of other obstetrical and nonobstetrical etiologies. Four women had steatosis diagnosed by sonography, and a fifth woman without sonographic abnormalities had biopsy-confirmed steatosis postpartum. Forbes and colleagues (2011) studied women with and without a history of gestational diabetes who had nondiabetic glucose tolerance testing postpartum. Although body mass index did not differ significantly, women with a history of gestational diabetes were more than twice as likely to have NAFLD diagnosed sonographically, and this correlated with increased dyslipidemia and measures of insulin resistance. As the obesity endemic worsens, any adverse effects of this liver disorder on pregnancy outcome should become apparent.
Irreversible chronic liver injury with extensive fibrosis and regenerative nodules is the final common pathway for several disorders. Laënnec cirrhosis from chronic alcohol exposure is the most frequent cause in the general population. But in young women—including pregnant women—most cases are caused by postnecrotic cirrhosis from chronic hepatitis B and C. Many cases of cryptogenic cirrhosis are now known to be caused by nonalcoholic fatty liver disease (Dienstag, 2012b). Clinical manifestations of cirrhosis include jaundice, edema, coagulopathy, metabolic abnormalities, and portal hypertension with gastroesophageal varices and splenomegaly. The incidence of deep-vein thromboembolism is increased (Søgaard, 2009). The prognosis is poor, and 75 percent have progressive disease that leads to death in 1 to 5 years.
Cirrhosis and Pregnancy
Women with symptomatic cirrhosis frequently are infertile. Those who become pregnant generally have poor outcomes. Common complications include transient hepatic failure, variceal hemorrhage, preterm delivery, fetal-growth restriction, and maternal death (Tan, 2008). Outcomes are generally worse if there are coexisting esophageal varices.
Another potentially fatal complication of cirrhosis arises from associated splenic artery aneurysms. Up to 20 percent of ruptures occur during pregnancy, and 70 percent of these rupture in the third trimester (Tan, 2008). In a review of 32 cases of these aneurysms, Ha and coworkers (2009) found that the mean diameter was 2.25 cm, and in half of cases, the diameter was < 2 cm. The maternal mortality rate of 22 percent was likely related to the emergent diagnosis of these cases, as almost all were diagnosed at the time of rupture.
Portal Hypertension and Esophageal Varices
Approximately half of esophageal varices cases in pregnant women are caused by either cirrhosis or extrahepatic portal vein obstruction, which leads to portal system hypertension. Some cases of extrahepatic hypertension develop following portal vein thrombosis associated with one of the thrombophilia syndromes (Chap. 52, p. 1029). Others follow thrombosis from umbilical vein catheterization when the woman was a neonate, especially if she was born preterm.
With either intrahepatic or extrahepatic resistance to flow, portal vein pressure rises from its normal range of 5 to 10 mm Hg, and values may exceed 30 mm Hg. Collateral circulation develops that carries portal blood to the systemic circulation. Drainage is via the gastric, intercostal, and other veins to the esophageal system, where varices develop. Bleeding is usually from varices near the gastroesophageal junction, and hemorrhage can be torrential. Bleeding during pregnancy from varices occurs in a third to half of affected women and is the major cause of maternal mortality (Tan, 2008).
Maternal prognosis is largely dependent on whether there is variceal hemorrhage. Mortality rates are higher if varices are associated with cirrhosis compared with rates for varices without cirrhosis—18 versus 2 percent, respectively. Perinatal mortality rates are high in women with varices and are worse if cirrhosis caused the varices.
Treatment is the same as for nonpregnant patients. Preventatively, all patients with cirrhosis, including pregnant women, should undergo screening endoscopy for identification of variceal dilatation (Tan, 2008). Beta-blocking drugs such as propranolol are given to reduce portal pressure and hence the bleeding risk (Groszmann, 2005).
For acute bleeding, endoscopic band ligation is preferred to sclerotherapy, as it avoids any potential risks of injecting sclerotherapeutic chemicals (Tan, 2008). Zeeman and Moise (1999) described a pregnant woman who underwent prophylactic banding at 15, 26, and 31 weeks’ gestation to prevent bleeding. Acute medical management for bleeding varices verified by endoscopy includes intravenous vasopressin or octreotide and somatostatin (Chung, 2005). Balloon tamponade using a triple-lumen tube placed into the esophagus and stomach to compress bleeding varices can be lifesaving if endoscopy is not available. The interventional radiology procedure—transjugular intrahepatic portosystemic stent shunting (TIPSS)—can also control bleeding from gastric varices that is unresponsive to other measures (Khan, 2006; Tan, 2008). TIPSS can be done electively in patients with previous variceal hemorrhage.
Acute Acetaminophen Overdose
Nonsteroidal antiinflammatory drugs (NSAIDs) are often used in suicide attempts. In a study from Denmark, Flint and associates (2002) reported that more than half of such attempts by 122 pregnant women were with either acetaminophen or aspirin. In the United States, acetaminophen is much more commonly used during pregnancy, and overdose may lead to hepatocellular necrosis and acute liver failure (Lee, 2008). Massive necrosis causes a cytokine storm and multiorgan dysfunction. Early symptoms of overdose are nausea, vomiting, diaphoresis, malaise, and pallor. After a latent period of 24 to 48 hours, liver failure ensues and usually begins to resolve in 5 days. In a prospective Danish study, only 35 percent of patients who were treated for fulminant hepatic failure spontaneously recovered before being listed for liver transplantation (Schmidt, 2007).
The antidote is N-acetylcysteine, which must be given promptly. The drug is thought to act by increasing glutathione levels, which aid metabolism of the toxic metabolite, N-acetyl-para-benzoquinoneimine. The need for treatment is based on projections of possible plasma hepatotoxic levels as a function of the time from acute ingestion. Many poison control centers use the nomogram established by Rumack and Matthew (1975). A plasma level is measured 4 hours after ingestion, and if the level is > 120 μg/mL, treatment is given. If plasma determinations are not available, empirical treatment is given if the ingested amount exceeded 7.5 g. An oral loading dose of 140 mg/kg of N-acetylcysteine is followed by 17 maintenance doses of 70 mg/kg every 4 hours for 72 hours of total treatment time. Both the oral and an equally efficacious intravenous dosing regimen have been recently reviewed by Hodgman and Garrard (2012). Although the drug reaches therapeutic concentrations in the fetus, any protective effects are unknown (Heard, 2008).
After 14 weeks, the fetus has some cytochrome P450 activity necessary for metabolism of acetaminophen to the toxic metabolite. Riggs and colleagues (1989) reported follow-up data from the Rocky Mountain Poison and Drug Center in 60 such women. The likelihood of maternal and fetal survival was better if the antidote was given soon after overdose. At least one 33-week fetus appears to have died as a direct result of hepatotoxicity 2 days after maternal ingestion. In another case, Wang and associates (1997) confirmed acetaminophen placental transfer with maternal and cord blood levels that measured 41 μg/mL. Both mother and infant died from hepatorenal failure.
Focal Nodular Hyperplasia
This is considered a benign lesion of the liver, characterized in most cases by a well-delineated accumulation of normal but disordered hepatocytes that surround a central stellate scar. These usually can be differentiated from hepatic adenomas by MR and CT imaging. Except in the rare situation of unremitting pain, surgery is rarely indicated, and most women remain asymptomatic during pregnancy. Rifai and coworkers (2013) reviewed 20 cases at a single center in Germany. None of the women had complications during pregnancy, and tumor size did not vary significantly before, during, or after pregnancy. Three women had 20-percent tumor growth; in 10 patients, the tumor decreased in size; and the remaining seven were unchanged across pregnancy. Ramirez-Fuentes and associates (2013) studied 44 lesions in 30 women, who each had a minimum of two MR imaging studies 12 months apart. They reported that 80 percent of the lesions were unchanged in size, and most of the remainder decreased in size. They concluded that changes in size were unrelated to pregnancy, oral contraceptive use, or menopause. As noted in Chapter 38 (p. 709), this lesion is not a contraindication to estrogen-containing contraceptives.
This benign neoplasm has a significant risk of rupture-associated hemorrhage, particularly in pregnancy. As discussed above, adenomas can usually be differentiated from focal nodular hyperplasia by MR or CT imaging. Adenomas have a 9:1 predominance among women and are strongly linked with combination oral contraceptive use. The risk of rupture increases with lesion size, and surgery is generally recommended for tumors measuring > 5 cm. From their review, Cobey and Salem (2004) found 27 cases in pregnancy, 23 of which became apparent in the third trimester and puerperium. They found no cases of hemorrhage when the tumor size was < 6.5 cm. In their review, 16 of 27 (60 percent) women with an adenoma presented with tumor rupture that resulted in seven maternal deaths and six fetal deaths. Of note, 13 of 27 women presented within 2 months postpartum, and in half, hemorrhage heralded rupture. Santambrogio and coworkers (2009) provided a case report of a woman with a 12-cm adenoma that ruptured shortly after emergent cesarean for placental abruption and that ultimately prompted liver transplantation.
According to the Organ Procurement and Transplantation Network (2012), liver transplant patients comprise nearly 18 percent of all proposed waiting organ recipients. Approximately a fourth of these are women of childbearing age. The first human liver transplant was performed 50 years ago, and a recent literature review cited 450 pregnancies in 306 women who had undergone transplantation (Deshpande, 2012). Although their livebirth rate of 80 percent and miscarriage rates compared favorably with those of the general population, there were significantly increased risks of preeclampsia, cesarean delivery, and preterm birth. A fourth of pregnancies were complicated by hypertension, approximately a third resulted in preterm birth, and in 10 percent, there was one or more rejection episodes (Table 55-4). Importantly, 4 percent of mothers had died within a year after delivery, but this rate is comparable with nonpregnant liver transplantation patients.
TABLE 55-4. Pregnancy Complications (%) in 558 Pregnancies after Liver Transplantation
In pregnant women who have undergone transplantation, close surveillance is mandatory to detect hypertension, renal dysfunction, preeclampsia, and graft rejection. Management considerations, including immunosuppressive therapy, were reviewed by Mastrobattista and Gomez-Lobo (2008) and by McKay and Josephson (2006). Because of increased metabolic clearance, serum levels of some antirejection drugs should be determined. Ethical considerations of pregnancy in transplant recipients were reviewed earlier by Ross (2006).
Cholelithiasis and Cholecystitis
In the United States, 20 percent of women older than 40 years have gallstones. Most stones contain cholesterol, and its oversecretion into bile is thought to be a major factor in stone formation. Biliary sludge, which may increase during pregnancy, is an important precursor to gallstone formation. The incidence of sonographically identified asymptomatic gallstones in more than 1500 pregnant or postpartum women was 2.5 to 10 percent (Maringhini, 1993; Valdivieso, 1993). Moreover, the cumulative risk of all patients with silent gallstones to require surgery for symptoms or complications is 10 percent at 5 years, 15 percent at 10 years, and 18 percent at 15 years (Greenberger, 2008). For these reasons, prophylactic cholecystectomy is not warranted for asymptomatic stones. For symptomatic gallstone disease, nonsurgical approaches have been used and include oral bile acid therapy with ursodeoxycholic acid and extracorporeal shock wave lithotripsy. There is no experience with these during pregnancy.
Acute cholecystitis usually develops when there is obstruction of the cystic duct. Bacterial infection plays a role in 50 to 85 percent of cases. In more than half of patients with acute cholecystitis, a history of previous right upper quadrant pain from cholelithiasis is elicited. With acute disease, pain is accompanied by anorexia, nausea and vomiting, low-grade fever, and mild leukocytosis. As shown in Figure 55-3, sonography can be used to see stones as small as 2 mm, and false-positive and false-negative rates are 2 to 4 percent (Greenberger, 2008).
FIGURE 55-3 This sonogram shows multiple hyperechoic gallstones filling an anechoic gallbladder.
Symptomatic gallbladder disorders in young women include acute cholecystitis, biliary colic, and acute pancreatitis. Rarely, a gallbladder undergoes torsion or a neoplasm is found (Kleiss, 2003; Wiseman, 2008). In most symptomatic patients, cholecystectomy is warranted. Although acute cholecystitis responds to medical therapy, contemporary consensus is that early cholecystectomy is indicated (Greenberger, 2008). In acute cases, medical therapy consists of intravenous fluids, antimicrobials, analgesics, and in some instances, nasogastric suction, before surgical therapy. Laparoscopic cholecystectomy has become the preferred treatment for most patients.
Gallbladder Disease During Pregnancy
The incidence of cholecystitis during pregnancy is reported to be approximately 1 in 1000. There is no doubt that pregnancy is “lithogenic.” After the first trimester, the gallbladder fasting volume as well as the residual volume after postprandial emptying are doubled. Incomplete emptying may result in retention of cholesterol crystals, a prerequisite for cholesterol gallstones. Maringhini and colleagues (1993) showed that the incidence of biliary sludge—which can be a forerunner to gallstones—and gallstones in pregnancy are 31 and 2 percent, respectively. Ko and colleagues (2014), however, cited a combined incidence to be lower at about 5 percent. Postpartum, there is frequently regression of sludge, and occasionally gallstones will resorb. Still, after delivery, hospitalization for gallbladder disease within a year remains relatively common. Ko (2006) studied Washington state discharge databases and documented that 0.5 percent of postpartum women were hospitalized within a year for various conditions. Of these 6211 women, 76 had uncomplicated cholecystitis, and 55 underwent cholecystectomy.
Medical versus Surgical Management
Acute cholecystitis during pregnancy or the puerperium is usually associated with gallstones or biliary sludge. Symptomatic cholecystitis is initially managed in a manner similar to that for nonpregnant women. In the past, most favored medical therapy. However, the recurrence rate during the same pregnancy is high, and 25 to 50 percent of women ultimately required cholecystectomy for persistent symptoms. Moreover, if cholecystitis recurs later in gestation, preterm labor is more likely and cholecystectomy technically more difficult.
For these reasons, operative and endoscopic interventions are increasingly favored over conservative measures. Othman and coworkers (2012) showed that women managed conservatively had more pain, more recurrent visits to the emergency department, more hospitalizations, and a higher rate of cesarean delivery. Dhupar and associates (2010) reported more complications with conservative management of gallbladder disease compared with laparoscopic cholecystectomy in pregnancy. These included multiple admissions, prolonged total parenteral nutrition, and unplanned labor induction for worsening gallbladder symptoms.
Cholecystectomy was performed safely in all trimesters. Only one of 19 patients who underwent laparoscopic cholecystectomy had a complication, which did not require further surgery. Date and coworkers (2008) reviewed the literature and found no increased risk of preterm birth or fetal demise for operative compared with conservative management. There was, however, a significantly higher rate of fetal death from gallstone pancreatitis when women were managed conservatively compared with surgical management. There were no perinatal deaths in 20 women undergoing cholecystectomy and in nine undergoing endoscopic retrograde cholangiopancreatography. Management at Parkland Hospital has evolved to a more aggressive surgical approach, especially if there is concomitant biliary pancreatitis as subsequently discussed. During the past two decades, laparoscopic cholecystectomy has evolved as the favored surgical approach and is discussed in Chapter 46 (p. 928).
Endoscopic Retrograde Cholangiopancreatography
Relief from symptomatic biliary duct gallstones during pregnancy has been greatly aided by use of endoscopic retrograde cholangiopancreatography—ERCP (Fogel, 2014; Menees, 2006). The procedure is performed if there is suspected or proven common duct obstruction, usually from stones. Approximately 10 percent of patients with symptomatic stone disease have common duct stones (Greenberger, 2008). ERCP can be modified in many cases so that radiation exposure from fluoroscopy is avoided (Shelton, 2008; Simmons, 2004).
Tang and associates (2009) reported results from 68 ERCP procedures performed in 65 pregnant women at Parkland Hospital. All but two women had gallstones, and sphincterotomy was performed in all but one woman. Common-duct stones were identified in half of these 65 women, and in all but one, the stones were successfully removed. A biliary stent was placed in 22 percent and removed after delivery. Complications were minimal, and post-ERCP pancreatitis developed in 16 percent. Pregnancy outcomes were not different than for the general obstetrical population. As a less invasive approach, magnetic resonance cholangiopancreatography (MRCP) has been reported to have utility in pregnancy, particularly with otherwise unexplained biliary duct dilatation identified sonographically (Oto, 2009). Use of MRCP in this situation identified the cause of the biliary ductal dilatation in four cases and excluded obstructive pathology in the remaining four cases.
Acute pancreatic inflammation is triggered by activation of pancreatic trypsinogen followed by autodigestion. It is characterized by cellular membrane disruption and proteolysis, edema, hemorrhage, and necrosis (Fogel, 2014; Whitcomb, 2006). Approximately 20 percent have severe pancreatitis, and mortality rates in these patients reach up to 25 percent (Swaroop, 2004).
In nonpregnant patients, acute pancreatitis is almost equally associated with gallstones and alcohol abuse. During pregnancy, however, cholelithiasis is almost always the predisposing condition. Other causes are hyperlipidemias, usually hypertriglyceridemia; hyperparathyroidism; congenital ductal anomalies; and rarely autoimmune pancreatitis (Crisan, 2008; Finkelberg, 2006). Nonbiliary pancreatitis occasionally develops postoperatively, or it is associated with trauma, drugs, or some viral infections. Certain metabolic conditions, including acute fatty liver of pregnancy and familial hypertriglyceridemia, also predispose to pancreatitis (Nelson, 2013). Acute and chronic pancreatitis have been linked to the more than 1000 mutations of the cystic fibrosis transmembrane conductance regulator gene (Rowntree, 2003).
At Parkland Hospital, with a large Mexican American population, acute pancreatitis complicated approximately 1 in 3300 pregnancies (Ramin, 1995). At Brigham and Women’s Hospital, with a more diversely ethnic population, Hernandez and colleagues (2007) reported an incidence of 1 in 4450. In a multiple-institution Midwestern three-state review of more than 305,000 pregnancies, Eddy and associates (2008) found the incidence of acute pancreatitis to be 1 in 3450.
Acute pancreatitis is characterized by mild to incapacitating epigastric pain, nausea and vomiting, and abdominal distention. Patients are usually in distress and have low-grade fever, tachycardia, hypotension, and abdominal tenderness. As many as 10 percent have systemic inflammatory response syndrome, which causes endothelial activation and can lead to acute respiratory distress syndrome (Chap. 47, p. 943).
Laboratory confirmation is from serum amylase levels three times upper normal values. As shown in Table 55-5, the mean amylase value was approximately 2000 IU/L in 173 pregnant women with pancreatitis, and the mean lipase value approximated 3000 IU/L. Importantly, there is no correlation between the degree of enzyme elevation and disease severity. Indeed, by 48 to 72 hours, amylase levels may return to normal despite other evidence for continuing pancreatitis. Serum lipase activity is also increased and usually remains elevated with continued inflammation. There is usually leukocytosis, and 25 percent of patients have hypocalcemia. Elevated serum bilirubin and aspartate aminotransferase levels may signify gallstone disease.
TABLE 55-5. Laboratory Values in 173 Pregnant Women with Acute Pancreatitis
Several prognostic factors may be used to predict disease severity (Whitcomb, 2006). Some of these are respiratory failure, shock, need for massive colloid replacement, hypocalcemia < 8 mg/dL, and dark hemorrhagic fluid removed with paracentesis. If three of the first four features are documented, survival is only 30 percent.
Medical treatment is the same as that for nonpregnant patients and includes analgesics, intravenous hydration, and measures to decrease pancreatic secretion by interdiction of oral intake. Other than supportive therapy, no particular treatment schemes have improved outcomes (Whitcomb, 2006). In the series by Ramin and colleagues (1995), all 43 affected pregnant women responded to conservative treatment and were hospitalized for a mean of 8.5 days. Nasogastric suction does not improve outcomes of mild to moderate disease, but enteral feeding may be helpful once pain improves and associated ileus resolves. Although we try to avoid parenteral nutrition, in 65 women with acute pancreatitis described by Eddy and coworkers (2008), a fourth had total parenteral nutrition. If there is bacterial superinfection of necrotizing pancreatitis, then antimicrobials are indicated. If common duct stones are found, then ERCP is indicated (Fogel, 2014). For pregnant patients with gallstone pancreatitis, ERCP for removal of common duct stones and papillotomy has been used successfully (Simmons, 2004; Tang, 2009). Cholecystectomy should be considered after inflammation subsides if there is gallbladder disease. Hernandez and associates (2007) reported that half of such women who did not undergo cholecystectomy had recurrent pancreatitis during the same pregnancy. Severe necrotizing pancreatitis can be life threatening, and laparotomy for debridement and drainage may be required (Gosnell, 2001; Robertson, 2006).
Pregnancy outcomes appear to be related to acute pancreatitis severity. Eddy and associates (2008) reported a 30-percent preterm delivery rate, and 11 percent were delivered before 35 weeks’ gestation. There were two pancreatitis-related deaths. Importantly, almost a third of 73 women had recurrent pancreatitis during pregnancy.
According to the United Network for Organ Sharing, the 5-year graft survival for pancreatic transplantation is 80 percent. Because there is improved survival when a combined pancreas and kidney are grafted for those with type 1 diabetes and renal failure, most transplants include both organs.
Mastrobattista and Gomez-Lobo (2008) reported results from the National Transplantation Pregnancy Registry. Of 44 pregnancies in 73 women following pancreas-kidney transplantation, outcomes have been encouraging, and vaginal delivery has been described. Although the incidence of hypertension, preeclampsia, preterm delivery, and fetal-growth restriction was high, there was only one perinatal death. There were four rejection episodes during pregnancy, which were treated successfully.
Pancreatic islet autotransplantation may be performed to prevent diabetes following pancreatectomy, and at least three successful pregnancies have been described (Jung, 2007).
Airoldi J, Berghella V: Hepatitis C and pregnancy. Obstet Gynecol Surv 61: 666, 2006
American College of Obstetricians and Gynecologists: Upper gastrointestinal tract, biliary, and pancreatic disorders. Clinical Updates in Women’s Health Care, Vol. XI, No. 4, 2012a
American College of Obstetricians and Gynecologists: Viral hepatitis in pregnancy. Practice Bulletin No. 86, October 2007, Reaffirmed 2012b
Anzivino C, Odoardi MR, Meschiari E, et al: ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Dig Liver Dis 45(3):226, 2013
Arshad M, El-Kamary SS, Jhaveri R: Hepatitis C virus infection during pregnancy and the newborn period—are they opportunities for treatment? J Viral Hepat 18(4):229, 2011
Babik JM, Cohan D, Monto A, et al: The human fetal immune response to hepatitis C virus exposure in utero. J Infect Dis 203(2):196, 2011
Bacq Y, Sentilhes L, Reyes HB, et al: Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 143(6):1492, 2012
Baskin B, Geraghty M, Ray PN: Paternal isodisomy of chromosome 2 as a cause of long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Am J Med Genet A 152A(7):1808, 2010
Berkley EMF, Leslie KK, Arora S, et al: Chronic hepatitis C in pregnancy. Am J Obstet Gynecol 112(2 Pt 1):304, 2008
Bernal W, Wendon J: Acute liver failure. N Engl J Med 369(26):2525, 2013
Blume C, Sensoy A, Gross MM, et al: A comparison of the outcome of pregnancies after liver and kidney transplantation. Transplantation 95(1):222, 2013
Borkakoti J, Hazam RK, Mohammad A, et al: Does high viral load of hepatitis E virus influence the severity and prognosis of acute liver failure during pregnancy? J Med Virol 85(4):620, 2013
Browning JD, Szczepaniak LS, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40(6):1387, 2004
Browning MF, Levy HL, Wilkins-Haug LE, et al: Fetal fatty acid oxidation defects and maternal liver disease in pregnancy. Obstet Gynecol 107:115, 2006
Candia L, Marquez J, Espinoza LR: Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma. Semin Arthritis Rheum 35:49, 2005
Castro MA, Ouzounian JG, Colletti PM, et al: Radiologic studies in acute fatty liver of pregnancy. A review of the literature and 19 new cases. J Reprod Med 41:839, 1996
Centers for Disease Control and Prevention: Surveillance for acute viral hepatitis—United States, 2006. MMWR 57(2):1, 2008
Centers for Disease Control and Prevention: Sexually transmitted diseases guidelines, 2010. MMWR 59(1):1, 2010
Centers for Disease Control and Prevention: Viral Hepatitis Surveillance United States, 2010. August 20, 2012. Available at: http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/. Accessed August 14, 2013
Ch’ng CL, Morgan M, Hainsworth I, et al: Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut 51(6):876, 2002
Christopher V, Al-Chalabi T, Richardson PD, et al: Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl 12:1037, 2006
Chung RT, Podolsky DK: Cirrhosis and its complications. In Kasper DL, Braunwald E, Fauci AS, et al (eds): Harrison’s Principles of Internal Medicine, 16th ed. New York, McGraw-Hill, 2005, p 1858
Cobey FC, Salem RR: A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 187(2):181, 2004
Connell LE, Salihu HM, Salemi JL, et al: Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 31(8):1163, 2011
Coscia LA, Constantinescu S, Moritz MJ, et al: Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2010:65
Cottrell EB, Chou R, Wasson N, et al: Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review of the U.S. Preventive Services Task Force. Ann Intern Med 158(2):109, 2013
Crisan LS, Steidl ET, Rivera-Alsina ME: Acute hyperlipidemic pancreatitis in pregnancy. Am J Obstet Gynecol 198(5):e57, 2008
Cunningham FG, Lowe TW, Guss S, et al: Erythrocyte morphology in women with severe preeclampsia and eclampsia. Am J Obstet Gynecol 153:358, 1985
Date RS, Kaushal M, Ramesh A: A review of the management of gallstone disease and its complications in pregnancy. Am J Surg 196(4):599, 2008
Daudi N, Shouval D, Stein-Zamir C, et al: Breastmilk hepatitis A virus DNA in nursing mothers with acute hepatitis A virus infection. Breastfeed Med 7:313, 2012
Davit-Spraul A, Gonzales E, Baussan C, et al: The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 30(2):134, 2010
Davit-Spraul A, Gonzales E, Jacquemin E: NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations. Clin Res Hepatol Gastroenterol 36(6):569, 2012
Deng M, Zhou X, Gao S, et al: The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 9:185, 2012
Deshpande NA, James NT, Kucirka LM, et al: Pregnancy outcomes of liver transplant recipients: a systematic review and meta-analysis. Liver Transpl 18(6):621, 2012
Dhupar R, Smaldone GM, Hamad GG. Is there a benefit to delaying cholecystectomy for symptomatic gallbladder disease during pregnancy? Surg Endosc 24(1):108, 2010
Dienstag JL: Acute viral hepatitis. In Longo DL, Fauci AS, Kasper DL, et al (eds) Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012a
Dienstag JL: Chronic hepatitis. In Longo DL, Fauci AS, Kasper DL, et al (eds) Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012b
Dixon PH, Wadsworth CA, Chambers J, et al: A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 109:76, 2014
Dusheiko G: Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis? Lancet 379(9830):2019, 2012
Eddy JJ, Gideonsen MD, Song JY, et al: Pancreatitis in pregnancy. Obstet Gynecol 112:1075, 2008
Ferrero S, Lungaro P, Bruzzone BM, et al: Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990–2000). Acta Obstet Gynecol Scand 82:229, 2003
Fesenmeier MF, Coppage KH, Lambers DS, et al: Acute fatty liver of pregnancy in 3 tertiary care centers. Am J Obstet Gynecol 192:1416, 2005
Feucht HH, Zollner B, Polywka S, et al: Vertical transmission of hepatitis G. Lancet 347:615, 1996
Finkelberg DL, Sahani D, Deshpande V, et al: Autoimmune pancreatitis. N Engl J Med 355:2670, 2006
Flint C, Larsen H, Nielsen GL, et al: Pregnancy outcome after suicide attempt by drug use: a Danish population-based study. Acta Obstet Gynecol Scand 81:516, 2002
Fogel EL, Sherman S: ERCP for gallstone pancreatitis. N Engl J Med 370:150, 2014
Forbes S, Taylor-Robinson SD, Patel N, et al: Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia 54(3):641, 2011
Franco J, Newcomer J, Adams M, et al: Auxiliary liver transplant in acute fatty liver of pregnancy. Obstet Gynecol 95:1042, 2000
Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, et al: Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV–mothers: a meta-analysis. Arch Gynecol Obstet 283(2):255, 2011
Giles M, Visvanathan K, Sasadeusz J: Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. Antivir Ther 16(5):621, 2011
Glantz A, Marschall H, Lammert F, et al: Intrahepatic Cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 42:1399, 2005
Glantz A, Marschall H, Mattsson L: Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 40:467, 2004
Gorelik J, Patel P, Ng’andwe C, et al: Genes encoding bile acid, phospholipid and anion transporters are expressed in a human fetal cardiomyocyte culture. BJOG 113:552, 2006
Gosnell FE, O’Neill BB, Harris HW: Necrotizing pancreatitis during pregnancy: a rare case and review of the literature. J Gastrointest Surg 5:371, 2001
Gossard AA, Lindor KD: Autoimmune hepatitis: a review. J Gastroenterol 47(5):498, 2012
Greenberger NJ, Paumgartner G: Diseases of the gallbladder and bile ducts. In Fauci AS, Braunwald E, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 17th ed. New York, McGraw-Hill, 2008, p 1991
Groszmann RJ, Garcia-Tsao G, Bosch J, et al: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353:2254, 2005
Ha JF, Phillips M, Faulkner K: Splenic artery aneurysm rupture in pregnancy. Eur J Obstet Gynecol Reprod Biol 146(2):133, 2009
Han L, Zhang HW, Xie JX, et al: A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 17(38):4321, 2011
Heard KJ: Acetylcysteine for acetaminophen poisoning. N Engl J Med 359: 285, 2008
Hernandez A, Petrov MS, Brooks DC, et al: Acute pancreatitis and pregnancy: a 10-year single center experience. J Gastrointest Surg 11:1623, 2007
Hill JB, Sheffield JS, Kim MJ, et al: Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 99(6):1049, 2002
Hodgman MJ, Garrard AR: A review of acetaminophen poisoning. Crit Care Clin 28(4):499, 2012
Hoofnagle JH, Nelson KE, Purcell RH: Hepatitis E. N Engl J Med 367:13, 2012
Hu Y, Zhang S, Luo C, et al: Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-base study in China. BMC Infect Dis 12:221, 2012
Inaba N, Okajima Y, Kang XS, et al: Maternal–infant transmission of hepatitis G virus. Am J Obstet Gynecol 177:1537, 1997
Indolfi G, Azzari C, Resti M: Hepatitis: immunoregulation in pregnancy and perinatal transmission of HCV. Nat Rev Gastroenterol Hepatol 11:6, 2014
Isoherranen N, Thummel KE: Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 41(2):256, 2013
Jabiry-Zieniewicz Z, Szpotanska-Sikorska M, Pietrzak B, et al: Pregnancy outcomes among female recipients after liver transplantation: further experience. Transplant Proc 43(8):3043, 2011
Jain AB, Reyes J, Marcos A, et al: Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years. Transplantation 76(5):827, 2003
Joshi D, James A, Quaglia A, et al: Liver disease in pregnancy. Lancet 375(9714):594, 2010
Jung HS, Choi SH, Noh JH, et al: Healthy twin birth after autologous islet transplantation in a pancreatectomized patient due to a benign tumor. Transplant Proc 39(5):1723, 2007
Khan S, Tudur Smith C, Williamson P, et al: Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev 4:CD000553, 2006
Kleiss K, Choy-Hee L, Fogle R, et al: Torsion of the gallbladder in pregnancy: a case report. J Reprod Med 48:206, 2003
Knight M, Nelson-Piercy C, Kurinczuk JJ, et al: A prospective national study of acute fatty liver of pregnancy in the UK. Gut 57(7):951, 2008
Ko CW: Risk factors for gallstone-related hospitalization during pregnancy and the postpartum. Am J Gastroenterol 101(10):2263, 2006
Ko CW, Napolitano PG, Lee SP, et al: Physical activity, maternal metabolic measures, and the incidence of gallbladder sludge or stones during pregnancy: a randomized trial. Am J Perinatol 31:39, 2014
Kondrackiene J, Beuers U, Kupcinskas L: Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129:894, 2005
Krawitt EL: Autoimmune hepatitis. N Engl J Med 354:54, 2006
Labrique AB, Sikder SS, Krain LJ, et al: Hepatitis E, a vaccine-preventable cause of maternal deaths. Emerg Infect Dis 18(9):1401, 2012
Lausman AY, Al-Yaseen E, Sam E, et al: Intrahepatic cholestasis of pregnancy in women with a multiple pregnancy: an analysis of risks and pregnancy outcomes. J Obstet Gynaecol Can 30(11):1008, 2008
Lee RH, Goodwin TM, Greenspoon J, et al: The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 26(9):527, 2006
Lee RH, Incerpi MH, Miller DA, et al: Sudden death in intrahepatic cholestasis of pregnancy. Obstet Gynecol 113(2):528, 2009
Lee WM, Squires RH Jr, Nyberg SL, et al: Acute liver failure: Summary of a workshop. Hepatology 47:1401, 2008
Levene AP, Goldin RD: The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61(2):141, 2012
Liang TJ, Ghany MG: Current and future therapies for hepatitis C virus infection. N Engl J Med 368(20):1907, 2013
Liu M, Cai H, Yi W: Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 20(Suppl 1):65, 2013
Lok AS, Gardiner DF, Lawitz E, et al: Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366(3):216, 2012
López M, Coll O: Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations. Fetal Diagn Ther 28(1):1, 2010
Lou H, Ding W, Dong M, et al: The presence of hepatitis B surface antigen in the ova of pregnant women and its relationship with intra-uterine infection by hepatitis B virus. J Int Med Res 38(1):214, 2010
Lucangioli SE, Castaño G, Contin MD, et al: Lithocholic acid as a biomarker of intrahepatic cholestasis of pregnancy during ursodeoxycholic acid treatment. Ann Clin Biochem 46(1):44, 2009
Maringhini A, Ciambra M, Baccelliere P, et al: Biliary sludge and gallstones in pregnancy: incidence, risk factors, and natural history. Ann Intern Med 119(2):116, 1993
Marschall HU, Shemer EW, Ludvigsson JF, et al: Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population based cohort study. Hepatology 58(4):1385, 2013
Martin JN Jr, Briery CM, Rose CH, et al: Postpartum plasma exchange as adjunctive therapy for severe acute fatty liver of pregnancy. J Clin Apher 23(4):138, 2008
Mastrobattista JM, Gomez-Lobo V: Pregnancy after solid organ transplantation. Obstet Gynecol 112:919, 2008
Matos A, Bernardes J, Ayres-de-Campos D, et al: Antepartum fetal cerebral hemorrhage not predicted by current surveillance methods in cholestasis of pregnancy. Obstet Gynecol 89:803, 1997
McCullough AJ: Thiazolidinediones for nonalcoholic steatohepatitis—promising but not ready for prime time. N Engl J Med 355:2361, 2006
McKay DB, Josephson MA: Pregnancy in recipients of solid organs—Effects on mother and child. N Engl J Med 354:1281, 2006
McMenamin MB, Jackson AD, Lambert J, et al: Obstetric management of hepatitis C-positive mothers: analysis of vertical transmission in 559 mother-infant pairs. Am J Obstet Gynecol 199:315.e1, 2008
Mehta S, Singla A, Rajaram S: Prognostic factors for fulminant viral hepatitis in pregnancy. Int J Gynaecol Obstet 118(2):172, 2012
Menees S, Elta G: Endoscopic retrograde cholangiopancreatography during pregnancy. Gastrointest Endoscopy Clin North Am 16:41, 2006
Mufti AR, Reau N: Liver disease in pregnancy. Clin Liver Dis 16(2):247, 2012
Müllenbach R, Bennett A, Tetlow N, et al: ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 54(6):829, 2005
Nagy S, Bush MC, Berkowitz R, et al: Pregnancy outcome in liver transplant recipients. Obstet Gynecol 102(1):121, 2003
Nayeri UA, Werner EF, Han CS, et al: Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. Am J Obstet Gynecol 207(3):231.e1, 2012
Nelson DB, Yost NP, Cunningham FG: Acute fatty liver of pregnancy: clinical outcomes and expected durations of recovery. Am J Obstet Gynecol 209(5):456.e1, 2013
Organ Procurement and Transplantation Network: 2011 Annual data report. 2012. Available at: http://srtr.transplant.hrsa.gov/annual_reports/2011/default.aspx. Accessed August 16,2013
Othman MO, Stone E, Hashimi M, et al: Conservative management of cholelithiasis and its complications in pregnancy is associated with recurrent symptoms and more emergency department visits. Gastrointest Endosc 76(3):564, 2012
Oto A, Ernst R, Ghulmiyyah L, et al: The role of MR cholangiopancreatography in the evaluation of pregnant patients with acute pancreaticobiliary disease. Br J Radiol 82(976):279, 2009
Page L, Girling J: A novel cause for abnormal liver function tests in pregnancy and the puerperium: non-alcoholic fatty liver disease. BJOG 118(12):1532, 2011
Pan CQ, Han GR, Jiang HX, et al: Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 10(5):520, 2012a
Pan CQ, Mi LJ, Bunchorntavakul C, et al: Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 57(9):2423, 2012b
Paternoster DM, Fabris F, Palù G, et al: Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection. Acta Obstet Gynecol Scand 81:99, 2002
Pereira SP, O’Donohue J, Wendon J, et al: Maternal and perinatal outcome in severe pregnancy-related liver disease. Hepatology 26:1258, 1997
Pergam SA, Wang CC, Gardella CM, et al: Pregnancy complications associated with hepatitis C: data from a 2003–2005 Washington state birth cohort. Am J Obstet Gynecol 199:38.e1, 2008
Poordad F, Lawitz E, Kowdley KV, et al: Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368:1, 2013
Ramin KD, Ramin SM, Richey SD, et al: Acute pancreatitis in pregnancy. Am J Obstet Gynecol 173:187, 1995
Ramírez-Fuentes C, Martí-Bonmatí L, Torregrosa A, et al: Variations in the size of focal nodular hyperplasia on magnetic resonance imaging. Radiologia 55(6):499, 2013
Reau N: Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol 12:114, 2014
Reddick KLB, Jhaveri R, Gandhi M, et al: Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 18(7):e394, 2011
Rein DB, Stevens GA, Theaker J, et al: The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55(4):988, 2012
Reyes H: Intrahepatic cholestasis. A puzzling disorder of pregnancy. J Gastroenterol Hepatol 12:211, 1997
Rifai K, Mix H, Krusche S, et al: No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy. Scand J Gastroenterol 48(1):88, 2013
Riggs BS, Bronstein AC, Kulig K, et al: Acute acetaminophen overdose during pregnancy. Obstet Gynecol 74:247, 1989
Roberts SS, Miller RK, Jones JK, et al: The Ribavirin Pregnancy Registry: findings after 5 years of enrollment, 2003–2009. Birth Defects Res A Clin Mol Teratol 88(7):551, 2010
Robertson KW, Stewart IS, Imrie CW: Severe acute pancreatitis and pregnancy. Pancreatology 6:309, 2006
Rook M, Vargas J, Caughey A, et al: Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. PLoS One 7(3):e28343, 2012
Ross LF: Ethical considerations related to pregnancy in transplant recipients. N Engl J Med 354:1313, 2006
Rowntree RK, Harris A: The phenotypic consequences of CFTR mutations. Ann Hum Genet 67:471, 2003
Rumack BH, Matthew H: Acetaminophen poisoning and toxicity. Pediatrics 55:871, 1975
Sadler LC, Lane M, North R: Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 102:169, 1995
Safir A, Levy A, Sikuler E, et al: Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 30(5):765, 2010
Salam GD, Kumar A, Kar P, et al: Serum tumor necrosis factor-alpha level in hepatitis E virus-related acute viral hepatitis and fulminant hepatic failure in pregnant women. Hepatol Res 43(8):826, 2013
Santambrogio R, Marconi AM, Ceretti AP, et al: Liver transplantation for spontaneous intrapartum rupture of a hepatic adenoma. Obstet Gynecol 113(2 Pt 2):508, 2009
Santiago-Munoz P, Roberts S, Sheffield J, et al: Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 193:1270, 2005
Santos L, Patterson A, Moreea SM, et al: Acute liver failure in pregnancy associated with maternal MCAD deficiency. J Inherit Metab Dis 30(1):103, 2007
Schmidt LE, Larsen FS: MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 45(3):789, 2007
Schramm C, Herkel J, Beuers U, et al: Pregnancy in autoimmune hepatitis: Outcome and risk factors. Am J Gastroenterol 101:556, 2006
Sheffield J, Roberts S, Laibl V, et al: The efficacy of an accelerated hepatitis B vaccination program during pregnancy [Abstract No. 212]. Am J Obstet Gynecol 195:S73, 2006
Sheiner E, Ohel I, Levy A, et al: Pregnancy outcome in women with pruritus gravidarum. J Reprod Med 51:394, 2006
Shelton J, Linder JD, Rivera-Alsina ME, et al: Commitment, confirmation, and clearance: new techniques for nonradiation ERCP during pregnancy (with videos). Gastrointest Endosc 67:364, 2008
Shi Z, Tang Y, Wang H, et al: Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med 165(9):837, 2011
Shi Z, Yang Y, Ma L, et al: Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus. A systematic review and meta-analysis. Obstet Gynecol 116(1):147, 2010
Sibai BM: Imitators of severe preeclampsia. Obstet Gynecol 109:956, 2007
Sibanda N, Briggs JD, Davison JM, et al: Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation 83:1301, 2007
Simmons DC, Tarnasky PR, Rivera-Alsina ME, et al: Endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy without the use of radiation. Am J Obstet Gynecol 190:1467, 2004
Sims HF, Brackett JC, Powell CK, et al: The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 92:841, 1995
Smith EA, Jacques-Carroll L, Walker TY, et al: The National Perinatal Hepatitis B Prevention Program, 1994–2008. Pediatrics 129(4):609, 2012
Søgaard KK, Horváth-Puhó E, Grønback H, et al: Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 104(1):96, 2009
Stewart RD, Sheffield JS: Hepatitis B vaccination in pregnancy in the United States. Vaccines 1(2):167, 2013
Strehlow SL, Pathak B, Goodwin TM, et al: The mechanical PR interval in fetuses of women with intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 203(5):455.e1, 2010
Swaroop VS, Chari ST, Clain JE: Severe acute pancreatitis. JAMA 291:2865, 2004
Tan J, Surti B, Saab S: Pregnancy and cirrhosis. Liver Transpl 14(8):1081, 2008
Tang S, Mayo MJ, Rodriguez-Frias E, et al: Safety and utility of ERCP during pregnancy. Gastrointest Endosc 69:453, 2009
Tang SJ, Rodriguez-Frias E, Singh S, et al: Acute pancreatitis during pregnancy. Clin Gastroenterol Hepatol 8(1):85, 2010
Towers CV, Asrat T, Rumney P: The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 184:1514, 2001
Turhan AN, Gönenç M, Kapan S, et al: Acute biliary pancreatitis related with pregnancy: a 5-year single center experience. Ulus Travma Acil Cerrahi Derg 16(2):160, 2010
Urganci N, Arapoglu M, Akyildiz B, et al: Neonatal cholestasis resulting from vertical transmission of hepatitis A infection. Pediatr Infect Dis J 22(4):381, 2003
Uribe M, Chavez-Tapia NC, Mendez-Sanchez N: Pregnancy and autoimmune hepatitis. Ann Hepatol 5(3):187, 2006
Usta IM, Barton JR, Amon EA, et al: Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourteen cases. Am J Obstet Gynecol 171:1342, 1994
Valdivieso V, Covarrubias C, Siegel F, et al: Pregnancy and cholelithiasis: pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 17:1, 1993
Victor JC, Monto AS, Surdina TY, et al: Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 357:1685, 2007
Vigil-De Gracia P, Lavergne JA: Acute fatty liver of pregnancy. Int J Gynaecol Obstet 72(2):193, 2001
Vigil-de Gracia P, Montufar-Rueda C: Acute fatty liver of pregnancy: diagnosis, treatment, and outcome based on 35 consecutive cases. J Matern Fetal Neonatal Med 24(9):1143, 2011
Wang PH, Yang MJ, Lee WL, et al: Acetaminophen poisoning in late pregnancy. A case report. J Reprod Med 42:367, 1997
Webb GJ, Elsharkawy AM, Hirschfield G: Editorial: the etiology of intrahepatic cholestasis of pregnancy: towards solving a monkey puzzle. Am J Gastroenterol 109:85, 2014
Wedemeyer H, Pischke S, Manns MP: Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 142(6):1388, 2012
Welsh JA, Karpen S, Vos MB: Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr 162(3):496.e1, 2013
Westbrook RH, Yeoman AD, Kriese S, et al: Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun 38(2–3):J239, 2012
Whitcomb DC: Acute pancreatitis. N Engl J Med 354:2142, 2006
Wikström Shemer E, Marschall HU, Ludvigsson JF, et al: Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG 120(6):717, 2013
Wiseman JE, Yamamoto M, Nguyen TD, et al: Cystic pancreatic neoplasm in pregnancy: a case report and review of the literature. Arch Surg 143(1):84, 2008
World Health Organization: Weekly epidemiological Record 84(40):405, 2009
Wu T, Zhu FC, Huang SJ, et al: Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 55(6):2038, 2012
Xu WM, Cui YT, Wang L, et al: Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 16(2):94, 2009
Yi W, Liu M, Cai HD: Safety of lamivudine treatment for hepatitis B in early pregnancy. World J Gastroenterol 18(45):6645, 2012
Ylitalo K, Vänttinen T, Halmesmäki E, et al: Serious pregnancy complications in a patient with previously undiagnosed carnitine palmitoyltransferase 1 deficiency. Am J Obstet Gynecol 192:2060, 2005
Yu M, Jiang Q, Ji Y, et al: The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus. Eur J Clin Microbiol Infect Dis 31(9):2211, 2012
Zeeman GG, Moise KJ: Prophylactic banding of severe esophageal varices associated with liver cirrhosis in pregnancy. Obstet Gynecol 94:842, 1999